Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease.

Eitemau Tebyg

• Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.
  gan: Kempf, D J, et al.
  Cyhoeddwyd: (1997)
• Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.
  gan: Ho, D D, et al.
  Cyhoeddwyd: (1994)
• In Vitro Antiviral Interaction of Lopinavir with Other Protease Inhibitors
  gan: Molla, Akhteruzzaman, et al.
  Cyhoeddwyd: (2002)
• Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.
  gan: Kaplan, A H, et al.
  Cyhoeddwyd: (1994)
• ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
  gan: Kempf, D J, et al.
  Cyhoeddwyd: (1995)